

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (FG-216)

PEGCETACOPLAN

PRONUNCIATION

peg set" a koe' plan


THERAPEUTIC CLAIM

Treatment of paroxysmal nocturnal hemoglobinuria (PNH), complement-mediated nephropathies, and age-related macular degeneration (AMD)

CHEMICAL NAMES

1. Poly(oxy-1,2-ethanediyl), α -hydro- ω -hydroxy-, 15,15'-diester with *N*-acetyl-L-iso-leucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminy-L- α -aspartyl-L-tryptophylglycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-L-threonyl-2-[2-(2-aminoethoxy)ethoxy]acetyl-*N*⁶-carboxyl-L-lysine cyclic (2→12)-(disulfide)
2. *O, O'*-bis[(*S*², *S*¹²-cyclo{*N*-acetyl-L-iso-leucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminy-L- α -aspartyl-L-tryptophylglycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-L-threonyl-2-[2-(2-aminoethoxy)ethoxy]acetyl-L-lysineamide})-*N*^{6,15}-carbonyl]polyethylene glycol ($n = 800-1100$)

STRUCTURAL FORMULA



MOLECULAR FORMULA

$C_{170}H_{248}N_{50}O_{47}S_4 \cdot (C_2H_4O)_n$ ($n \sim 800-1100$)

MOLECULAR WEIGHT

~47 kDa

TRADEMARK

None as yet

SPONSOR

Apellis Pharmaceuticals

CODE DESIGNATION

APL-2

CAS REGISTRY NUMBER

2019171-69-6

UNII

TO3JYR3BOU

WHO NUMBER

10743

SCS